CollPlant is in advanced negotiations with a U.S. investor for a US $5.0MM private placement.
Funds would support 3D printing technology for tissues and organs, product development/commercialization and manufacturing upgrades. The investor would also assist in registering CollPlant on NASDAQ.
The company has developed Vergenix®STR Soft Tissue Repair Matrix to treat tendinopathy, which is exclusively distributed by Arthrex in Europe, the Middle East, India and Africa.
Sources: CollPlant; ORTHOWORLD Inc.
CollPlant is in advanced negotiations with a U.S. investor for a US $5.0MM private placement.
Funds would support 3D printing technology for tissues and organs, product development/commercialization and manufacturing upgrades. The investor would also assist in registering CollPlant on NASDAQ.
The company has developed Vergenix®STR Soft...
CollPlant is in advanced negotiations with a U.S. investor for a US $5.0MM private placement.
Funds would support 3D printing technology for tissues and organs, product development/commercialization and manufacturing upgrades. The investor would also assist in registering CollPlant on NASDAQ.
The company has developed Vergenix®STR Soft Tissue Repair Matrix to treat tendinopathy, which is exclusively distributed by Arthrex in Europe, the Middle East, India and Africa.
Sources: CollPlant; ORTHOWORLD Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.